Company intelligence / Profile preview

Biovica

Ownership: Private
Development stage: Commercial

Overview

DiviTum® TKa has been clinically validated in over 4,500 patients across multiple studies. It provides prognostic information at baseline and during CDK4/6 inhibitor therapy for metastatic breast cancer. The test enables early assessment of treatment efficacy within weeks of starting therapy.

Therapeutic areas: Oncology
Modalities: Blood-based biomarker assay
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

DiviTum TKa

Commercial

Indications: Breast cancer

Partnerships

Collaborations with leading cancer institutesCollaborative groupsPharmaceutical companies involved in product development

Beyond the preview

Go deeper on Biovica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biovica.

Explore the full profile